SAN DIEGO, Feb. 2, 2026 /PRNewswire/ -- Fulcrum, the AI-powered field process management and data collection platform, today announced the launch of Insights, a new AI-based capability that lets ...
SAN FRANCISCO--(BUSINESS WIRE)--Fulcrum, the leading AI platform for insurance brokerages, today announced $25 million in combined Seed and Series A funding led by CRV, with participation from South ...
Abstract: In modern software development, Python third-party libraries play a critical role, especially in fields like deep learning and scientific computing. However, API parameters in these ...
For the last two years, the fundamental unit of generative AI development has been the "completion." You send a text prompt to a model, it sends text back, and the transaction ends. If you want to ...
This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Cambridge-based Fulcrum Therapeutics said ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Hosted on MSN
Truist Securities Initiates Coverage of Fulcrum Therapeutics (FULC) with Buy Recommendation
Fintel reports that on November 24, 2025, Truist Securities initiated coverage of Fulcrum Therapeutics (NasdaqGM:FULC) with a Buy recommendation. Analyst Price Forecast Suggests 23.10% Upside As of ...
Join us for an exclusive webinar where we unveil our new Python API designed to streamline trading as a price taker in FX Options. Whether you are a seasoned quant or trader looking to incorporate ...
Plymouth-based medical benefits organization Fulcrum Health is launching a mobile clinic to deliver non-pharmacological treatments like acupuncture, massage and physical therapy to underserved ...
Fulcrum Therapeutics (NASDAQ:FULC) fell ~10% on Tuesday after the company posted data from a late-stage study of its lead candidate, Pociredir, in sickle cell disease, along with second quarter ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results